Project 2: Targeting Immunosuppression Pathways to Enhance Brain Tumor Immunotherapy. John H. Sampson, M.D., Ph.D., M.H.Sc, Project Leader Glioblastoma multiforme (GBM) is the most common of primary malignant brain tumors and despite incapacitating conventional therapy, remains universally fatal. Immunotherapy is an attractive therapeutic alternative, but is limited by the lack of frequent and homogeneously-expressed tumor-specific antigens and a profoundly immunosuppressive host environment. This proposal addresses both of these limitations. The nearly universal presence and homogeneous expression of CMV antigens in GBM, but not normal brain, has now been well-established and provides an unparalleled opportunity to subvert these highly immunogenic viral proteins as tumor-specific targets. Despite the potential immunogenicity of CMV antigens, endogenous immune responses may be limited, at least in part, by an excessive number of immunosuppressive T-cells (TRegs). TRegs are a phenotypically distinct CD4+ CD25 + Foxp3+ population that normally prevent autoimmunity and are uniquely dependent on the high affinity interleukin (lL)-2 receptor (IL-2Ra/CD25) for their function and survival. Monoclonal antibodies (MAbs) that block lL-2Ra have been shown to abrogate Tpeg function in animal models but can also inhibit effective anti-tumor immune responses in mice and humans. Our preliminary data demonstrates that treatment with lL-2Ra blocking MAbs in mice undergoing homeostatic proliferation in response to transient lymphodepletion, as might be seen after therapeutic cycles of chemotherapy, still eliminates Tpegs, but in stark contrast, no longer impairs effector Tcell immune responses. Instead, vaccine-induced immune responses are strongly accentuated. This may be due to homeostatic surges in y receptor cytokines (IL-7 and IL-15) that share receptors with IL-2 and may bypass the need and effects of IL-2 signaling in activated T-cells in this context Preliminary clinical studies show that patients vaccinated with CMV pp65 mRNA transfected dendritic cells and then treated with a commercially-available MAb specific for the human IL-2Ra after therapeutic TMZ chemotherapy, have reduced Tpeg levels, increased pp65-specific CDS* T-cell responses, and progression-free survival interval of 27.4 months. In this proposal, we will test the HYPOTHESIS that during hematopoietic recovery from treatment-induced lymphopenia TRegs can be selectively inhibited by anti-lL2Ra MAbs to enhance anti-tumor immunity without the induction of limiting autoimmunity.

Public Health Relevance

Treatment for malignant primary brain tumors is ineffective and represents the most expensive medical therapy per quality-adjusted life-year saved currently provided in the USA. Conventional therapy is limited by non-specific toxicity, and immunotherapy has been limited by the lack of frequent and homogeneously expressed tumor-specific antigens and a profoundly immunosuppressive host environment. This proposal addresses all of these limitations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA154291-01A1
Application #
8236388
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Project Start
Project End
Budget Start
2012-07-11
Budget End
2013-06-30
Support Year
1
Fiscal Year
2012
Total Cost
$411,884
Indirect Cost
$148,542
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Bao, Xuhui; Chandramohan, Vidyalakshmi; Reynolds, Randall P et al. (2016) Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats. Invest New Drugs 34:149-58
Suryadevara, Carter M; Riccione, Katherine A; Sampson, John H (2016) Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity. Clin Cancer Res 22:5164-5166
Saraswathula, Anirudh; Reap, Elizabeth A; Choi, Bryan D et al. (2016) Serum elevation of B lymphocyte stimulator does not increase regulatory B cells in glioblastoma patients undergoing immunotherapy. Cancer Immunol Immunother 65:205-11
Mitchell, Duane A; Batich, Kristen A; Gunn, Michael D et al. (2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 519:366-9
Pruszyński, Marek; Łyczko, Monika; Bilewicz, Aleksander et al. (2015) Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals. Nucl Med Biol 42:439-45
Huang, Dong-Sheng; Wang, Zhaohui; He, Xu-Jun et al. (2015) Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer 51:969-76
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2015) D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination. Nucl Med Biol 42:19-27
Pruszynski, Marek; Koumarianou, Eftychia; Vaidyanathan, Ganesan et al. (2014) Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med 55:650-6
Choi, Jaeyeon; Vaidyanathan, Ganesan; Koumarianou, Eftychia et al. (2014) N-Succinimidyl guanidinomethyl iodobenzoate protein radiohalogenation agents: influence of isomeric substitution on radiolabeling and target cell residualization. Nucl Med Biol 41:802-12
Congdon, Kendra L; Gedeon, Patrick C; Suryadevara, Carter M et al. (2014) Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol 16 Suppl 8:viii20-5

Showing the most recent 10 out of 19 publications